On September 15, 2022, Caladrius Biosciences and Cend Therapeutics announced the closing of their merger. The merged company will now operate as Lisata Therapeutics, Inc. and will commence trading on The Nasdaq Capital Market under the ticker symbol “LSTA”.
Developing Innovative Therapies thatTreat or Reverse Disease
Caladrius Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and promote the regeneration of damaged tissue.
Our proprietary CD34+ cell therapy platform has generated a multi-product development pipeline with the potential to provide curative therapies to people in need.
Our mission is to discover, develop and deliver innovative therapeutics in areas of unmet medical need that improve patient lives. We can accomplish that goal through the collective efforts of talented individuals who work together to advance scientific research. We place a premium on integrity, respect, diversity and collaboration. These values have helped us to build a growing company that offers professionally rewarding careers with the opportunity to make a meaningful contribution to patients in need.
On September 15, 2022, Caladrius Biosciences and Cend Therapeutics announced the closing of their merger. The merged company will now operate as Lisata Therapeutics, Inc. and will commence trading on The Nasdaq Capital Market under the ticker symbol “LSTA”.
